Integra Lifesciences Holdings Corp
XMUN:IL3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Integra Lifesciences Holdings Corp
XMUN:IL3
|
US |
|
Douyu International Holdings Ltd
NASDAQ:DOYU
|
CN |
|
J
|
JTL Industries Ltd
BSE:534600
|
IN |
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
PAR:AI
|
FR |
Integra Lifesciences Holdings Corp
Integra LifeSciences makes medical devices and biologic products used in surgery, especially in neurosurgery, brain and spine procedures, wound repair, and other complex operations. Its products include surgical instruments, implants, nerve repair products, dural substitutes, and tissue-based materials that help doctors close wounds, protect tissue, and support healing. Its main customers are hospitals, surgeons, ambulatory surgery centers, and other healthcare providers. Integra makes money by selling these products directly to customers and through distributors, with demand tied to the number and type of surgeries performed. Because many of its products are used in specialized procedures, it sits in a niche part of the healthcare market rather than in everyday consumer medicine. What makes the business model different is that it combines traditional medical devices with regenerative tissue products. That gives it exposure to both hardware-like surgical tools and more specialized biologic products that are used in critical care and reconstruction. In practice, Integra is a supplier to doctors and hospitals that need precise tools and materials for difficult surgeries and wound treatment.
Integra LifeSciences makes medical devices and biologic products used in surgery, especially in neurosurgery, brain and spine procedures, wound repair, and other complex operations. Its products include surgical instruments, implants, nerve repair products, dural substitutes, and tissue-based materials that help doctors close wounds, protect tissue, and support healing.
Its main customers are hospitals, surgeons, ambulatory surgery centers, and other healthcare providers. Integra makes money by selling these products directly to customers and through distributors, with demand tied to the number and type of surgeries performed. Because many of its products are used in specialized procedures, it sits in a niche part of the healthcare market rather than in everyday consumer medicine.
What makes the business model different is that it combines traditional medical devices with regenerative tissue products. That gives it exposure to both hardware-like surgical tools and more specialized biologic products that are used in critical care and reconstruction. In practice, Integra is a supplier to doctors and hospitals that need precise tools and materials for difficult surgeries and wound treatment.
Strong quarter: Integra reported Q1 revenue of $392 million and adjusted EPS of $0.54, both above the high end of guidance.
Guidance: The company kept full-year revenue guidance unchanged at $1.66 billion to $1.7 billion, while raising adjusted EPS guidance to $2.40 to $2.50.
Leadership shift: Stuart Essig returned as President and CEO, saying the company is staying the course on transformation while putting more emphasis on customers and commercial execution.
Supply improving: Management said better product availability and remediation progress were major drivers of the quarter and should support a more steady revenue cadence through the year.
Wound momentum: Tissue Reconstruction posted strong growth, helped by Integra Skin, DuraSorb and PriMatrix, and management sounded upbeat about the business despite changes in skin substitute reimbursement.
Longer-term upside: The company expects SurgiMend to return to market in Q4 2026, with PMA approvals for SurgiMend and DuraSorb expected in 2027 and meaningful breast reconstruction contribution beyond that.
